CEBPA mutation analysis-13554

Test info

CEBPA mutation analysis

The CEBPA (CCAAT/enhancer binding protein alpha) gene encodes a transcription factor important for granulocyte differentiation. CEBPA mutations are found in 6-15% of de novo acute myeloid leukemia (AML) and in 15-18% of AML with normal karyotypes. CEBPA mutations are associated with favorable prognosis in absence of associated cytogenetic abnormalities and FLT3 internal duplication (FLT3-ITD). Germline CEBPA mutations are a cause of nonsyndromic, familial AML.


EDTA whole blood
5 mL
3 mL

Lavender (EDTA), 4 mL


Sodium heparin (Na hep) whole blood
Bone marrow
Bone marrow - 2 mL (minimum 1.0 mL)

Whole blood

Dk green Sodium heparin (Na hep), no gel

Bone marrow

Lavender (EDTA), 4mL

Dk green Sodium heparin (Na hep), no gel



Molecular Medicare billing request

  • Complete and submit the form to notify us of the need for Allina Health Laboratory to bill insurance for Molecular testing performed
  • All information requested is required in order for your request to be completed

Ambient (preferred)


Specimen does not meet all of the above criteria for sample type, container, minimum volume, collection and storage.

Unsuitable specimens include but are not limited to:

  • frozen whole blood or marrow
  • a leaking tube
  • clotted blood or marrow
  • a grossly hemolyzed specimen or otherwise visibly degraded
  • specimen suspected of being contaminated by another specimen
  • specimen contains specific foreign material


LabCorp RTP (489170): R-LC
Mo - Fr
10 - 14 days

Polymerase chain reaction (PCR), direct sequencing and capillary electrophoresis

Clinical and Interpretive info


An interpretive report will be included


This test may require preauthorization from the insurance provider. Check the payer guidelines and, if needed, obtain the pre-authorization prior to sample collection.
Result 64012-8